In 2024, CR Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, CR Pharma has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 175,023.13a | 170,536.14a | 160,986.95a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 547,436.67a | 555,112.18a | 613,993.65a | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 4.9572a | 4.9529a | 5.1377a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of CR Pharma amounted to 722,459.8 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of CR Pharma decreased by 0.44%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2024, the total Scope 1 emissions of CR Pharma were 175,023.13 metric tons of CO₂ equivalent (tCO₂e).a
Since 2021, CR Pharma's Scope 1 emissions have increased by 43.74%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2023), CR Pharma's Scope 1 emissions increased by 2.63%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2024, CR Pharma reported Scope 2 greenhouse gas (GHG) emissions of 547,436.67 tCO₂e without specifying the calculation method.a
Since 2021, CR Pharma's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have remained relatively stable, indicating that CR Pharma's emissions have plateaued with no significant change in its energy consumption footprint.ab
Compared to the previous year (2023), CR Pharma's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that CR Pharma's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2024, CR Pharma reported its Scope 2 emissions using an unspecified methodology.a
In 2024, CR Pharma reported Scope 1 greenhouse gas (GHG) emissions of 175,023.13 tCO₂e and total revenues of USD 35,307 millions. This translates into an emissions intensity of 4.96 tCO₂e per millions USD.a
In 2024, CR Pharma reported a Scope 1 emissions intensity of 4.96 tCO₂e per millions USD. Compared to the peer group median of 14.5, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2024, CR Pharma ranked 4 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places CR Pharma among the top performers, with one of the lowest emissions intensities relative to peers.a